HP
AMAG

HealthInvest Partners’s AMAG Pharmaceuticals AMAG Stock Holding History

HealthInvest Partners’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-671,585
Closed -$16.1M – 17
2016
Q2 		$16.1M Sell
671,585
-69,000
-9% -$1.58M 7.37% 3
2016
Q1 		$17.3M Buy
740,585
+220,585
+42% +$5.24M 8.11% 5
2015
Q4 		$15.7M Buy
+520,000
New +$16.8M 7.39% 4

Other funds holding AMAG

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SIM
Stelliam Investment Management New York $404M AUM 5.1% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

HealthInvest Partners's AMAG Position: Q3 2016 in Review

HealthInvest Partners sold out of AMAG Pharmaceuticals (AMAG) in Q3 2016, closing a stake of 671,585 shares — an estimated $16.1M sold.

HealthInvest Partners first reported a position in AMAG in Q4 2015 and held it in 3 quarters. The position peaked at $17.3M in Q1 2016. 178 funds tracked by Wall St. Rank hold AMAG as of Q3 2016.

  • HealthInvest Partners reported no remaining AMAG Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • HealthInvest Partners sold 671,585 AMAG Pharmaceuticals shares in Q3 2016, an estimated $16.1M.
  • HealthInvest Partners first reported a position in AMAG Pharmaceuticals in Q4 2015 and held it in 3 quarters.
  • HealthInvest Partners's AMAG Pharmaceuticals position peaked at $17.3M in Q1 2016.
  • 178 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2016.

Based on HealthInvest Partners's 13F filing for Q3 2016, filed 24 Oct 2016.